Xcout Intel
Be Biopharma competitors & alternatives
The 12 closest competitors and alternatives to Be Biopharma among biotechnology companies — ranked by similarity to what Be Biopharma actually does, not by market-cap band.
Subscribe to see Be Biopharma’s full profile → the full roster, investors in every round, weekly hiring history and every corporate event
About Be Biopharma
Be Biopharma is a biopharmaceutical company headquartered in Cambridge, Massachusetts, focused on developing engineered B cell therapies.
Be Biopharma at a glance
Be Biopharma is a biotechnology company headquartered in United States. It has raised at least $144M across the 2 funding rounds on record. Its most recent funding round, Series C, raised $92M in January 2025. Xcout tracks 3 named people at Be Biopharma, including David Rawlings (co-founder).
Be Biopharma leadership
- David Rawlingsco-founder
- Lea Hachigianfounder
- Richard Jamesco-founder
Be Biopharma funding rounds
At least $144M raised across the 2 rounds on record. Every round on record:
| Date | Round | Amount | Investors |
|---|---|---|---|
| Series C | $92M | — | |
| Series A | $52M | 4 named |
Who invested in each round, lead investors, valuations and the co-investor graph — open the full funding history →
Top 12 Be Biopharma competitors
Ranked by semantic similarity — how close each company is to Be Biopharma by what it does, using Xcout's live company graph. Click any company for its full profile, or its competitor set.
Biotech
Beigene, now known as BeOne Medicines, is a multinational oncology company. It specializes in biotechnology research and the development of cancer treatment drugs, with headquarters located in Cambridge, Massachusetts.
Biotech
HiFiBio Therapeutics is a clinical-stage immune modulation biotechnology company headquartered in Cambridge, Massachusetts. The company focuses on discovering and developing novel precision antibody therapeutics for immunology and oncology applications.
Similar biotechnology company
BIND Therapeutics, Inc. is a clinical-stage nanomedicine company headquartered in Cambridge, Massachusetts. The company specializes in developing targeted and programmable therapeutics using its proprietary platform to treat various diseases.
Biotech
Bellicum Pharmaceuticals, Inc. is a company focused on engineering high-performance cellular immunotherapies. These therapies are developed to combat diseases.
Similar biotechnology company
Boston Immune Technologies and Therapeutics, Inc. (BITT) is a company headquartered in Winchester, Massachusetts, that specializes in the development of cancer treatments and therapeutics.
Similar biotechnology company
Walking Fish Therapeutics, Inc. is a biotechnology company headquartered in South San Francisco, California, focused on engineering B cell-based protein factories to develop novel biotherapeutics for treating serious diseases.
Similar biotechnology company
CREATE Medicines is a clinical-stage biotechnology company located in Cambridge, Massachusetts, pioneering in vivo immune programming with RNA.
Similar biotechnology company
BlueRock Therapeutics is a clinical-stage cell therapy company headquartered in Cambridge, Massachusetts, focused on developing engineered cellular medicines for degenerative conditions.
Biotech
Senda Biosciences is a biotechnology company focused on harnessing nature to program novel medicines, headquartered in Cambridge, Massachusetts.
Similar biotechnology company
Beam Therapeutics Inc., founded in 2017 and based in Cambridge, Massachusetts, operates as a pioneering biopharmaceutical firm. Its core mission involves engineering precise genetic remedies to tackle a spectrum of severe human ailments, primarily within the United States. The company's developmental portfolio features several key candidates: BEAM-101 is being advanced to treat both sickle cell disease and beta thalassemia. BEAM-102 is specifically designed for addressing sickle cell disease. BEAM-201, an allogeneic chimeric antigen receptor T-cell therapy, is under investigation for individuals suffering from relapsed or refractory T-cell acute lymphoblastic leukemia. BEAM-301 is a liver-targeted candidate aimed at patients afflicted with Glycogen Storage Disease Type Ia. Beyond these flagship programs, Beam Therapeutics is also engaged in devising treatments for alpha-1 antitrypsin deficiency, various ocular conditions, and other disorders impacting the liver, muscular system, and central nervous system. To further its research and development objectives, Beam Therapeutics has forged numerous strategic alliances and partnerships. These include collaborations with Boston Children's Hospital; a research and clinical trial agreement with Magenta Therapeutics, Inc.; a licensing deal with Sana Biotechnology, Inc.; and a research partnership with the Institute of Molecular and Clinical Ophthalmology Basel. Additionally, the company maintains research collaborations with both Pfizer Inc. and Apellis Pharmaceuticals, Inc., alongside a comprehensive collaboration and license agreement with Verve Therapeutics, Inc.
Similar biotechnology company
Stipple Bio, Inc. is a private biotechnology company headquartered in Cambridge, Massachusetts, United States, focused on harnessing epitope-level precision in therapeutics.
Similar biotechnology company
Checkmate Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company headquartered in Cambridge, Massachusetts, focused on developing proprietary technology to stimulate the immune system to combat cancer.
Analyze another company
Search any company we track to see its competitive set.
Or describe a company
Paste a short paragraph describing a company or product — we'll find the most similar companies we track, scored 1–100.
See the full profile of Be Biopharma and its market
Funding, investors, tech stack, hiring signals, leadership and corporate events — for Be Biopharmaand every competitor above — in one live dashboard.
Subscribe to Xcout Intel →